UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

At the close of business on Monday 17 March 2025: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was Net Asset Values are calculated in accordance with published ...

A: We anticipate safety and efficacy data for OCU200 by the end of this year. We are evaluating safety, BCVA, dose response, antibody formation, and pharmacokinetics. - Tiffany Hamilton ...

OCU200 moved into the clinic, and patients are currently being dosed in Phase 1 clinical trial for diabetic macular edema, ...

Ocugen’s biologic candidate moved into the clinic and patients are currently being dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). OCU200 has the potential to change ...